ONTX

Onconova Therapeutics, Inc.

0.69 USD
-0.14 (-16.82%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Onconova Therapeutics, Inc. stock is down -4.12% since 30 days ago. The next earnings date is Mar 14, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 March’s closed higher than February.

About Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma.